Independent Conference Highlights of the 2022 ASH Annual Meeting*

Long-term follow-up did not show improved survival with lenalidomide/dexamethasone induction, reduced-intensity melphalan, and transplant followed by lenalidomide maintenance vs continuous lenalidomide/dexamethasone in patients 60-75 years of age with newly diagnosed multiple myeloma.

Potentially curative therapy with KRd followed by ASCT, KRd consolidation, and lenalidomide maintenance in high-risk smoldering MM is encouraging, with 43% of patients MRD negative at 4 years and only 6% progressing to active MM.

MonumenTAL-1 trial showed an objective response rate of 73% to 74% with talquetamab in heavily pretreated patients with R/R MM.

Ide-cel demonstrated deep responses and manageable toxicity in patients with clinical high-risk MM and early relapse after first-line induction, ASCT, and lenalidomide maintenance.

In the dose-expansion cohort of a phase I/II trial, mezigdomide + dexamethasone showed promising efficacy with a manageable safety profile in patients with triple-class refractory relapsed/refractory multiple myeloma.

Among frail patients with newly diagnosed multiple myeloma, a dexamethasone-sparing regimen of daratumumab plus lenalidomide was associated with higher response rates and MRD negativity rates vs lenalidomide plus dexamethasone and had a favorable safety profile.

Data support improved PFS with continued lenalidomide maintenance beyond 4-5 years in patients with newly diagnosed multiple myeloma and for at least 3 years in patients with sustained MRD negativity.

Combination daratumumab/carfilzomib/lenalidomide/dexamethasone given for a fixed duration of 2 years was well tolerated and is associated with a high response rate in patients with high-risk smoldering multiple myeloma.

Intensified consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone showed clinical benefit in patients with ultra-high‒risk newly diagnosed multiple myeloma and primary plasma cell leukemia in the phase II OPTIMUM/MUKnine trial.

Patients who received idecabtagene vicleucel after previous BCMA-targeted therapy have high response rates but worse overall outcomes compared with patients who have not received previous BCMA-targeted therapy.